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4CEO FOREWORD
The Australian Criminal Intelligence Commission has a national responsibility to provide 
information and intelligence on criminal activity. Much of the harm that Australians suffer 
at the hands of organised crime is due to the trade in illicit substances and abuse of licit 
substances at the instigation of serious and organised crime groups who profit from 
importing, trafficking, manufacturing and selling drugs.
This National Wastewater Drug Monitoring Program report is the second in a series of nine 
public reports which will detail the findings of the national wastewater program until the 
end of 2019. This report provides statistically valid datasets of drug use and distribution 
patterns across a large number of sites in capital cities and regional areas. 
The National Wastewater Drug Monitoring Program is intended to provide a national picture 
of drug use and therefore demand. Regrettably, during the period covered by this report 
the operators of wastewater facilities in Tasmania and the Northern Territory declined 
to participate in the collection of samples, and hence there is no analysis of drug trends 
in those jurisdictions in this report. This is disappointing, as it limits our understanding 
of trends and emerging issues in those jurisdictions, and the ability to compare current 
findings with those published in the first report. The Australian Criminal Intelligence 
Commission will continue engaging with all jurisdictions to secure ongoing participation in 
sampling for future reports. Participation from all states and territories is vital to informing 
our understanding of the national picture of drug use and demand.
TRENDS IDENTIFIED DURING THIS REPORTING PERIOD
Although results from different jurisdictions vary, there was a slight but pleasing reduction 
in the level of methylamphetamine used nationally over the period covered by this report. 
It is too early to say with any confidence whether this result is part of a longer term trend. 
Independent reporting points to widespread harm being caused by the methylamphetamine 
market, so any sustained decline in the level of use nationally would be welcomed. Results 
from this reporting period continue to identify relatively high levels of methylamphetamine 
use in regional areas in a number of jurisdictions, which is problematic and poses significant 
challenges due to the relative scarcity of resources that can be employed locally to respond.
Methylamphetamine remains by far the most used illicit drug of those tested in the National 
Wastewater Drug Monitoring Program. Reduced licit and illicit use of the pharmaceutical 
opioids oxycodone and fentanyl was identified during the period covered by this report. 
However, the level of use still allows considerable scope for diversion to the illicit market. 
The Australian Criminal Intelligence Commission continues to monitor trends in relation to 
pharmaceutical opioids and to collaborate with the public and private sectors to develop a 
national response.
No significant changes were identified in the cocaine or MDMA markets nationally. 
Use of these substances continues to lag behind the use of methylamphetamine and 
pharmaceutical opioids by some margin. The use of tobacco increased nationally and in 
most jurisdictions during the period covered by this report.
5EVOLUTION OF THE PROGRAM
As I noted when the first National Wastewater Drug Monitoring Program report was 
released, wastewater analysis provides a measure of one important aspect of national 
health—the demand for a range of licit and illicit drugs. An understanding of this behaviour 
allows governments to effectively direct resources to priority areas, and also to monitor the 
progress of demand and supply reduction strategies. Against this background, it has been 
pleasing to note that a number of state and local government entities have approached the 
Australian Criminal Intelligence Commission for advice on drug trends in their particular 
area when planning responses. The Australian Criminal Intelligence Commission willingly 
works with agencies in these circumstances to ensure they have reliable contemporary data 
against which to judge the success of particular initiatives.
In future reports the Australian Criminal Intelligence Commission will test for the use of 
heroin and 3,4-methylenedioxyamphetamine (MDA). This reporting involves a natural 
evolution of the existing National Wastewater Drug Monitoring Program and we are grateful 
to our partners at the University of Queensland and University of South Australia for 
extending the existing program in this manner.
The baseline assessment of national drug consumption established by the first report 
of the National Wastewater Drug Monitoring Program has been complemented by the 
findings of this report and of other contemporary datasets. For example, findings from the 
Drug Use Monitoring in Australia program indicate that in 2015–16 the self-reported use 
of methylamphetamine overtook that of cannabis. For the first time, methylamphetamine 
became the most commonly reported illicit drug used by police detainees in the 12 months 
preceding interview. The proportion of detainees testing positive for methylamphetamine 
also increased in 2015–16 and was higher than the proportion testing positive for any other 
drug. The Australian Criminal Intelligence Commission remains committed to capturing and 
integrating additional datasets with our wastewater data to build a comprehensive and 
increasingly detailed picture of national drug consumption. 
I would like to thank the Minister for Justice for contributing the funding which made this 
initiative possible, and to acknowledge the Australian Criminal Intelligence Commission 
officers who contributed to the project. I am grateful for the valuable support and specialist 
expertise of Jochen Mueller, Wayne Hall, Sharon Grant, Ben Tscharke, Rachel Mackie and 
Jake O’Brien of the University of Queensland, and Jason White, Cobus Gerber, Richard Bade 
and Maulik Ghetia from the University of South Australia who undertook the data collection 
and analysis which underpins this report. 
 
Chris Dawson APM 
Chief Executive Officer 
Australian Criminal Intelligence Commission
6This report covers 
approximately 51 per cent of 
Australia’s population—about 
12.6 million Australians. 
Methylamphetamine remains 
the highest consumed illicit 
drug tested across all regions  
in Australia, though nationally 
there was a slight reduction.
Compared with 
methylamphetamine, 
consumption of other 
stimulants was generally 
much lower.
Alcohol and 
tobacco remain 
highest consumed 
substances in 
all states and 
territories.
51%
Oxycodone and fentanyl 
consumption (licit and illicit) 
across all jurisdictions 
continues at concerning levels.
Consumption  
levels for tested  
new psychoactive  
substances  
confirm this remains  
a niche market.
NT and Tas 
declined to 
participate*
*Operators of wastewater facilities in Tasmania and the Northern Territory declined to participate in the collection of samples during the period covered by this report.
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7METHYLAMPHETAMINE CONSUMPTION
Highest levels 
in SA and WA.
Capital city consumption exceeded regional sites.
COCAINE CONSUMPTION
While capital city NSW levels dominated the 
national landscape, ACT, Vic and regional Qld sites 
showed higher levels compared to other states.
Consumption in capital city 
locations was on average 
almost double that of 
regional sites. 
CONSUMPTION OF OTHER SUBSTANCES
SA and ACT 
capital city sites 
showed higher 
than average 
oxycodone levels.
Tobacco levels in 
Qld and WA are the 
highest across the 
nation.
NSW, SA and 
Qld regional 
sites had higher 
than average 
fentanyl levels.
MDMA CONSUMPTION
Consumption in 
ACT increased 
significantly in 
Dec 2016, before 
reducing to a 
relatively low level  
in Feb 2017.
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INTRODUCTION
This is the second in a series of nine National Wastewater Drug Monitoring Program reports 
to be publicly launched by the Australian Criminal Intelligence Commission. This program 
aims to deliver on the recommendations of the National Ice Taskforce’s final report. It is the 
first program to provide leading-edge, coordinated national research and intelligence on 
illicit and licit drugs, with a specific focus on methylamphetamine and 12 other substances.
In 2016, the Australian Criminal Intelligence Commission received $3.6 million in funding 
under the Proceeds of Crime Act to deliver the National Wastewater Drug Monitoring 
Program over three years. The program provides a measure, rather than an estimate, of the 
use of a number of illicit drugs, as well as licit drugs including nicotine, alcohol and some 
pharmaceuticals. It gives us valuable insight into the trends and emerging issues of drug 
consumption across Australia. 
The findings presented in the nine reports will give law enforcement, policy, regulatory and 
health agencies additional and more objective data on the use of methylamphetamine and 
other drugs. This data creates opportunities to shape the response to both the demand and 
the supply side of the illicit drug market, particularly in high-use areas.
IMPLEMENTATION
The Australian Criminal Intelligence Commission has contracted the University of 
Queensland and through it the University of South Australia to deliver the program. 
Relationships have been built between the universities and the operators of wastewater 
facilities across Australia to permit the collection and analysis of samples.
The contract provides that for the first 12 months the wastewater analysis will measure the 
presence1 of the following substances:
  methylamphetamine
  amphetamine
  cocaine
  3,4-methylenedioxymethamphetamine (MDMA)
  3,4-methylenedioxyamphetamine (MDA)
  JWH-018
  JWH-073
  mephedrone
  methylone
  oxycodone
  fentanyl
  tobacco
  alcohol.
1 The contract recognises that threshold levels are substance dependent and will vary accordingly. Refer to the report for 
further information on detection levels, and whether it was possible to measure all substances.
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The first five substances are widely recognised illicit stimulants. The next four substances 
are also illicit and are described as new psychoactive substances (NPS). JWH-018 and  
JWH-073 are synthetic cannabinoids, while mephedrone and methylone are synthetic 
stimulants. Oxycodone and fentanyl are pharmaceuticals with therapeutic application, but 
are also diverted to the illicit market. 
Both contracted universities will monitor wastewater at sites across Australia until the end 
of 2019. The capital city sites cover all state and territory capital cities, with the remaining 
sites covering regional cities and towns. The capital city sites will be monitored for the 
duration of the trial, while the remaining sites will be re-assessed periodically during the 
course of the program. 
Sites were selected to permit the Australian Criminal Intelligence Commission to provide 
data on major population areas, sites of actual or potential concern from a drug use 
perspective, and sites where the local authorities have established relationships with 
the two universities. During the period covered by this second report, entities operating 
wastewater treatment facilities in Tasmania and the Northern Territory declined to 
participate in the National Wastewater Drug Monitoring Program, reducing the number of 
sites monitored for this report. 
The breakdown by jurisdiction for the second report is as follows:
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The Australian Criminal Intelligence Commission will continue engaging with all jurisdictions 
to secure ongoing participation in sampling for future reports. Participation from all states 
and territories is vital to informing our understanding of the national picture of drug use 
and demand. In the event that one or more jurisdictions decide not to participate in the 
national program in the future, the Australian Criminal Intelligence Commission will identify 
replacement sites from participating jurisdictions to ensure that the largest possible 
segment of the national population is sampled. Accordingly, the location of sites within and 
between jurisdictions may change over the three years of the contract. 
The Australian Criminal Intelligence Commission is also reviewing the appropriateness of 
the selected substances with its partners, stakeholders and the universities. To this end, 
from the third report of the National Wastewater Drug Monitoring Program, heroin will 
be included in the list of drugs for which the samples are tested. The universities have also 
devised a method to distinguish between the MDA that exists in wastewater as a metabolite 
derived from MDMA consumption and the metabolites that derive from the consumption 
of MDA itself. This method will allow a distinction to be made between MDMA and MDA 
consumption in future reports.
REPORTING
National Wastewater Drug Monitoring Program reports will be published as comprehensive 
public reports three times a year, as per the program contract. In accordance with current 
wastewater analysis conventions, the terms of the contract, and to protect the integrity 
of the program, the exact locations of wastewater treatment plants will not be publicly 
released by the Australian Criminal Intelligence Commission. 
To maintain the confidentiality of the participating sites, each site was allocated a unique 
code so that results could be de-identified. However, trends in particular jurisdictions 
are still able to be identified. The public reports will incorporate a discussion of trends in 
drug use where distinct trends are seen—for example, between regional areas and capital 
cities, or between jurisdictions and nationally—and will include comparisons with testing 
from previous years where that data is available. Once each year, the report will include an 
assessment of where Australian consumption for some substances sits in comparison with 
international trends.2
Stakeholders in law enforcement, health and other relevant policy agencies will be given 
classified reports which identify actual sampling locations in order to inform appropriate 
responses. 
2 The data is only updated annually because, although Australian data is updated every four months, the comparable 
international data is only collated and updated annually.
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EXPLOITATION OF THE NATIONAL WASTEWATER DRUG 
MONITORING PROGRAM DATA 
The Australian Criminal Intelligence Commission intends that the findings of the National 
Wastewater Drug Monitoring Program analysis will be fundamental to the development 
of government policy and decision making, as the reports will provide a regular, timely, 
unambiguous and detailed measure of the level of demand for the listed commodities 
in the Australian population, complementing other drug datasets published in Australia. 
The second National Wastewater Drug Monitoring Program report measures drug use 
by approximately 51 per cent of the Australian population.3 It is hoped that wastewater 
data will be used to assess and validate other available data sources to obtain a more 
comprehensive and accurate understanding of drug markets nationally and in the respective 
jurisdictions. 
Findings from the first report of the National Wastewater Drug Monitoring Program have 
already been used by agencies from two jurisdictions to shape local responses to the 
methylamphetamine threat, and a local government entity from a third jurisdiction is using 
the data as part of its planning processes—evidence that the program is providing meaningful 
and actionable intelligence to inform Australia’s response to drug supply and demand.
Making the National Wastewater Drug Monitoring Program data available to the public and 
to public agencies will enrich understanding and inform the national conversation on trends 
in the demand for drugs. Because the collection and analysis protocols are similar, it will 
also be possible to compare domestic drug use with levels of use internationally, which may 
stimulate further discussions on alternative responses to the threat posed by drug use. 
The Australian Criminal Intelligence Commission is also considering methods of using 
National Wastewater Drug Monitoring Program data as a measure of the effectiveness 
of supply and demand reduction initiatives in selected locations around the country. The 
Australian Criminal Intelligence Commission is working to ensure the broadest possible 
range of stakeholders are engaged throughout the life of the program, consulting with 
stakeholders through existing drug forums and direct discussions with agencies. Since 
the release of the first public report in March 2017, the Australian Criminal Intelligence 
Commission has delivered a series of presentations to forums in Australia and New Zealand 
concerning the National Wastewater Drug Monitoring Program’s capability and the 
significant potential it offers for enhanced collaboration.
The National Wastewater Drug Monitoring Program is based on a well-established and 
internationally recognised methodology which has been applied to varying extents by many 
other nations. In the Australian context, wastewater has been identified as offering an 
important, unified and consistent guiding tool in developing holistic drug responses. To this 
end, the scope of the sampling will generate data which will help governments at both a 
state and national level to formulate appropriate responses.   
3 This estimate is based on the Australian Bureau of Statistics estimate of the Australian population as at 31 December 2016 
and catchment data supplied by the operators of the wastewater facilities and service providers for December 2016.
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RESULTS FROM THE INITIAL COLLECTION
Building on the baseline assessment of national drug consumption provided by the first 
public report, the second report of the National Wastewater Drug Monitoring Program 
contains data on drug use patterns across states, territories and the nation. It provides 
data on capital city and regional drug use and, where possible, comparisons with previous 
levels of use in sites across Australia. This and future reports will contribute further data to 
identify trends, changes in patterns of use and emerging issues—building a comprehensive 
and increasingly detailed picture of national drug consumption. 
Reported results reflect per capita use in all locations and are expressed in terms of both 
the number of doses and the weight or volume per capita of the respective substances, to 
facilitate comparison between substances.
13
RESEARCH FINDINGS
Prepared for the Australian Criminal Intelligence Commission by:
The University of Queensland 
(B Tscharke, R Mackie, J O’Brien, S Grant, J Mueller)
University of South Australia 
(R Bade, M Ghetia, C Gerber, J White)
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LIST OF ABBREVIATIONS
ABS  Australian Bureau of Statistics
ACIC  Australian Criminal Intelligence Commission
ACT  Australian Capital Territory
LC-MS/MS liquid chromatography tandem mass spectrometry
LOD  limit of detection
LOR  limit of reporting
MDA  3,4-methylenedioxyamphetamine
MDMA  3,4-methylenedioxymethylamphetamine
NSW  New South Wales
NT  Northern Territory
NWDMP National Wastewater Drug Monitoring Program
QA/QC  quality assurance and quality control
QLD   Queensland
SA  South Australia
TAS  Tasmania
VIC  Victoria
WA  Western Australia
WWTP  wastewater treatment plant
 
TERMINOLOGY
Methylamphetamine is also commonly known as methamphetamine. In this report, 
consistent with the preferences of the Australian Criminal Intelligence Commission, 
methylamphetamine is used.
MDMA is commonly known as ecstasy.
Alcohol consumption in this report refers to ethanol consumption but the more general 
term ‘alcohol’ is used throughout.
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1: EXECUTIVE SUMMARY
Wastewater analysis has become the standard for measuring population-scale use of a 
range of different chemical compounds. The underlying concepts involved in wastewater 
analysis were demonstrated in the first national Australian report which was released in 
March 2017. Estimates of drug usage in a population were back-calculated from measured 
concentrations of drug metabolites (excreted into the sewer system after consumption) in 
wastewater samples. Spatial and temporal trends in drug use have now been included using 
this approach for several sites across Australia. The National Wastewater Drug Monitoring 
Program (NWDMP) of the Australian Criminal Intelligence Commission (ACIC) aims to 
expand the monitoring of substances of concern to all regions of Australia. The study 
focuses on 13 licit and illicit drugs, including tobacco, alcohol, methylamphetamine, cocaine 
and MDMA (ecstasy). Trends in estimated drug consumption will be established over the 
three-year project. Wastewater treatment plants (WWTPs) located across capital cities and 
regional Australia, covering all states and territories, have been invited to participate in this 
program.
For this second report, wastewater samples were collected during weeks of October 
and December 2016, as well as February 2017. A total of 15 WWTPs in capital cities and 
a further 22 regional sites participated in the project for the December 2016 period, 
covering a population of more than 12.6 million Australians. Data from this report equates 
to coverage of approximately 58%, 30%, 54% and 52% of Australia’s population for the 
August, October, December and February periods, respectively. A total of 777 individual 
daily samples have been assessed since the beginning of the program, with results of 
448 samples from October to February reported for the first time here. Unlike the first 
reporting period which covered 51 sites in census week (August 2016), sites in the Northern 
Territory and Tasmania declined to provide subsequent samples, while an ongoing 
sampling regime was not in place to collect New South Wales and Queensland samples 
in October 2016. Nevertheless, the collected samples provide relatively comprehensive, 
Australia-wide baseline data against which subsequent data can continue to be compared 
to ascertain both spatial and temporal trends. Twenty-four-hour composite wastewater 
samples were collected using time-proportional or flow-proportional autosamplers at 
the influent of each WWTP by plant operators. Samples were collected for up to seven 
consecutive days. Concentrations of drug metabolites were determined in the wastewater 
using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analytical methods. 
Drug consumption estimates for each catchment population were calculated from these 
measured concentrations using flow volumes and estimates of the catchment population 
size provided by the treatment plants, together with excretion and dose data derived from 
the scientific literature. To maintain treatment plant confidentiality, each site was allocated 
a unique code and site names are not included in this report.
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Estimated drug usage across the 37 sites (December 2016) was highly variable, both 
between drugs and between sites. However, when the amount of drug measured 
in wastewater was normalised for population size and average dose consumed, 
alcohol and tobacco were consistently the highest consumed drugs in all states and 
territories. Estimated consumption of tobacco was generally highest in Queensland and 
Western Australia and some sites in regional New South Wales and Victoria. Alcohol 
consumption across the nation was similar for the most part. Amongst the illicit drugs, 
methylamphetamine consumption was the highest across all regions of Australia. This trend 
was consistent for both capital cities and regional sites and on average, regional and capital 
city Australia showed comparable levels of usage. The highest methylamphetamine levels 
were seen at Western Australian and South Australian sites (capital city and regional), as 
well as some regional sites in Queensland. Comparing the latest findings of drug use with 
previous data for sites in Queensland and South Australia, current methylamphetamine 
levels have shown a decline since historical highs in October 2016. 
Amphetamine is a metabolite of methylamphetamine and measured amphetamine 
concentrations across the sites were consistent with the observed levels being primarily 
related to methylamphetamine metabolism rather than sourced from direct consumption. 
Compared to methylamphetamine, estimated usage of other stimulants was generally 
much lower, although no consistent pattern (profile) of usage for these other drugs could 
be observed between states and territories. Cocaine usage in Australia is mostly centred in 
New South Wales across several capital city and regional sites. At sites elsewhere around 
the country usage was low in comparison. MDMA usage was similarly low across most sites 
with a few site-specific exceptions. 
Oxycodone and fentanyl, which are both pharmaceutical substances with abuse potential 
through diversion, had elevated consumption levels at several regional sites. It should be 
noted that it is not possible to distinguish between licit and illicit use of the substances. 
Regional areas had average oxycodone use well above capital city sites in most jurisdictions. 
For the other drugs included in this study, methylone and mephedrone, concentrations 
were generally at or below detection levels at all participating sites, while JWH-018 and 
JWH-073 were not detected in any samples.
The collection of wastewater samples at regular intervals allowed for the temporal 
comparison of consumption data. While small overall changes were evident at both a 
site and a state or territory level, sufficient data is not yet available to draw meaningful 
conclusions. Nevertheless, the recent declines in methylamphetamine use in South Australia 
and Western Australia were clear reversals in longer term trends. A gradual reduction in 
pharmaceutical opioid use, particularly oxycodone, was also apparent.
17
Australian Criminal Intelligence Commission 
National Wastewater Drug Monitoring Program—Report 2, July 2017
2: INTRODUCTION
2.1: PREAMBLE
Wastewater analysis is a technique for measuring population-scale consumption of 
substances. The University of Queensland and University of South Australia have been 
commissioned to provide drug consumption data to the ACIC for a period of three years, 
beginning in August 2016. A total of approximately 50 wastewater treatment sites will be 
assessed, bimonthly in the case of capital city sites and every four months for regional 
sites. The aim is to acquire data on the population-scale use of substances that cause 
potential harm, either through addiction, health risks, or criminal and anti-social behaviour. 
The intention is to establish baseline data of substance use across Australia. This second 
NWDMP report compares consumption data from the initial August 2016 analysis to data 
obtained from October and December 2016, and from February 2017. Invitations for 
inclusion in subsequent NWDMP collections were declined from sites in Tasmania and the 
Northern Territory. As such, no samples or data for those states have been collected or 
reported for the October, December or February periods. 
Compounds of concern include nicotine from tobacco, ethanol from alcohol intake, 
pharmaceutical opioids with abuse potential, illicit substances such as methylamphetamine, 
MDMA and cocaine, as well as a number of new psychoactive substances (NPS) including 
synthetic cannabinoids. The compounds amphetamine and MDA were measured but 
not included in the final report. Amphetamine is a by-product of methylamphetamine 
consumption and also one of its metabolites. MDA is a metabolite of MDMA. These 
substances will be included in future reports once there is greater certainty regarding the 
contribution from other drugs as opposed to ingested amphetamine and MDA. The report 
presents patterns of substance use across Australia, showing differences in levels between 
capital cities and regional centres within states and territories, and nationally.  
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3: METHODS
The method underlying wastewater based monitoring of drug use in a given population 
is based on the principle that any given compound that is consumed (irrespective of 
whether it is swallowed, inhaled/smoked or injected) will subsequently be excreted 
(either in the chemical form it is consumed and/or in a chemically modified form that is 
referred to as a metabolite). The excreted compound or metabolite will eventually arrive 
in the sewer system. The drugs and their metabolites of interest in this study are given 
in the first NWDMP report (available at www.acic.gov.au). Collectively, waste products in 
the sewer system arrive at a wastewater treatment plant where wastewater samples are 
collected over a defined sampling period. Measuring the amount of target compound in 
the wastewater stream allows for a back-calculation factor to be applied to determine the 
amount of drug that was used over the collection period (Figure 1). The method is non-
invasive and is done on a population-scale level, so individuals are not targeted and privacy 
is respected.
Figure 1: Schematic of the population catchment area and methodology employed to 
convert measured concentration of substances in wastewater to mass loads or doses 
consumed per day per normalised population. 
To obtain an estimate of drug use, representative samples are collected over a given period 
(typically 24 hours) using autosamplers that collect time or flow proportional samples. 
Wastewater treatment plant operators provide assistance with collecting the samples from 
the influent autosampler (where the wastewater enters the treatment plants). Details of the 
calculation methods are given in the first NWDMP report. 
Community 
services
e.g. hospitals/
universities/
prisons
Autosampler at 
WWTP
inlet
Community
Community-wide facilities
e.g. shopping malls/
hotels/events/
offices/
industry
CATCHMENT 
POPULATION
Wastewater 
treatment plant
(WWTP)
CONCENTRATION OF EXCRETED 
METABOLITE
(measured)
(wastewater entering the WWTP is sampled over a 
24 hour period.  The average concentration of 
metabolite is measured,
i.e. grams of metabolite per litre of wastewater) TOTAL MASS OF METABOLITE EXCRETED
(calculated)
(total grams of excreted metabolite that reaches 
the WWTP from the catchment in 24 hours)
MASS OF METABOLITE EXCRETED/1000 PEOPLE
(calculated)
(grams of metabolite excreted on average by 1000 people
in the catchment in 24 hours)
MASS OF DRUG CONSUMED/1000 PEOPLE
(calculated)
(grams of drug consumed on average by 1000 people 
in the catchment in 24 hours)
Multiply concentration by total volume 
of wastewater flowing into WWTP 
over 24 hours
Divide by catchment 
population 
(thousands of people)
DOSES OF DRUG CONSUMED/1000 PEOPLE
(calculated)
(number of doses of drug consumed on average by 1000 people 
in the catchment in 24 hours)
Divide by excretion rate i.e. 
the mass of metabolite 
excreted for every unit of drug 
consumed, and multiply by the 
difference in molecular weight 
between the drug and its’ 
metabolite
Divide by the mass of 
drug typically 
consumed in one go 
(i.e. the standard dose)
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Collected wastewater samples were analysed at the University of South Australia and the 
University of Queensland laboratories. The steps routinely performed in our laboratories 
are based on filtration of the samples followed by an enrichment/concentration step where 
the concentrated sample is injected, or (for chemicals with sufficiently high concentrations) 
direct injection of samples into the analytical instruments. The instrumental analysis 
consists of chromatographic separation and subsequent compound specific detection. A 
summary of the extraction and analytical methods is given in the first NWDMP report.
3.1: PARTICIPATING WASTEWATER TREATMENT PLANTS (WWTPs)
Thirty-seven WWTPs across Australia participated in this study for the December 2016 
collection (Figure 2). Of these, 15 sites were located in capital cities and a further 22 were 
regional sites covering a wide range of catchment population sizes. Sites were selected by 
the ACIC. The number of participating sites for August, October, December and February 
is listed in Table 1. A complete list of participating sites, number of samples and relative 
catchment sizes is listed in Appendix 1. To maintain the confidentiality of the participating 
sites, all sites were allocated a unique code to de-identify their results. Only site codes are 
presented in the results sections.
Figure 2: Participating WWTPs in December 2016, showing the split between capital 
city and regional plants by state and territory. The colours in this figure are used in the 
remainder of the report to identify results relating to individual states and territories.
3C
3R
Declined to 
participate
4C
5R
2C
8R
3C
3R 1C
2C
3R
C = Capital city WWTP
R = Regional WWTP
Participating WWTPs per State/Territory
Declined to 
participate
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Table 1: Number of Participating WWTPs for the periods covered in this report. Every second 
collection period aims to collect data from both regional and city sites (Aug and Dec), while 
the in-between collection periods (Oct and Feb) aim to collect data from city sites only.
AUG–16 OCT–16 DEC–16 FEB–17
State/territory C R C R C R C R
ACT 1 - - - 1 - 1 -
NSW 5 5 - - 3 3 3 -
NT 1 1 Declined to participate
Qld 3 9 - 1 2 8 3 1
SA 4 4 4 - 4 5 4 -
Tas 3 4 Declined to participate
Vic 2 5 2 - 2 3 2 -
WA 3 1 3 1 3 3 3 3
Total Population 
(millions) 12.1 2.0 6.8 0.04 11.2 1.4 11.9 0.2
 
3.2: SAMPLE COLLECTION AND PREPARATION
Composite samples were collected by treatment plant staff daily on seven consecutive days 
from Monday to Sunday, or where seven days was not feasible, across as many consecutive 
days as possible. Samples were stored at 4oC or were frozen prior to transport to Adelaide 
or Brisbane, respectively. Further details of the sampling protocol and relevant quality 
controls are included in Irvine et al. (2011), Lai et al. (2011), Lai et al. (2015), Tscharke et 
al. (2016). All other descriptions of calculations, extractions and analytical methods are 
outlined in the first NWDMP report.
3.3: PRESENTATION OF DATA AND INTERPRETATION OF GRAPHS
Reported averages: All averages for state/territory or Australia-wide drug consumption 
data are presented throughout this report as population weighted averages. The number 
of people in the catchment population is used as the weighting for the respective drug 
consumption data for that population. For example, to calculate the population weighted 
average of capital city methylamphetamine consumption, the methylamphetamine 
consumption data for each WWTP was multiplied by the respective population number, 
all data were then summed and divided by the total population across all capital city sites. 
Reported average values are therefore not skewed towards usage data from small, non-
representative populations.
21
Australian Criminal Intelligence Commission 
National Wastewater Drug Monitoring Program—Report 2, July 2017
Per capita consumption: The per capita consumption estimates presented in this report are 
calculated using the total estimated catchment population (which includes children). For 
example, per capita alcohol consumption has previously been reported by the ABS based 
on population numbers for people aged 15 and over. The consumption values presented 
in the current report will be under-estimated compared to those determined for an adult-
only population. For consistency, data from other studies included in this report were 
recalculated where necessary using estimated total population. 
Graphical presentation of data: An overview of how the data is presented in the graphs 
for the individual sites is given in Figure 3. This includes information on interpreting the 
consumption data presented on the vertical axes in all graphs in this report; in some graphs, 
the values plotted in the graph can be read as either mass of drug consumed (left axis) or 
doses of drug consumed (right axis). 
Figure 3: Explanation of the graphical representation of data for individual sites. General 
concepts relevant to all graphs in the report are also outlined (unique site codes, 
explanation of vertical axes, colour coding).
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Instrumental method limits of detection and limits of reporting: Since the wastewater 
samples contain very low quantities of particular drugs, the limit of detection (LOD) was 
determined analytically as the lowest concentration of that drug that could be distinguished 
in the sample (using the methods described in Report 1). A drug may be present at a 
concentration below the LOD. However, trace quantities may actually be present at 
undetectable levels. The limit of reporting (LOR) is a concentration (higher than the LOD), 
above which we have high confidence that the concentration measured on the analytical 
instrument is accurate. Above the LOD but below the LOR there may be some uncertainty 
as to the actual concentration. To be conservative (a drug may be present but there is 
uncertainty as to its concentration) and in line with current practise, for back calculations 
to estimate per capita consumption, a concentration below the LOD is included at a value 
of LOD. A concentration above the LOD but below LOR, is included at the midpoint between 
the LOD and LOR (i.e. (LOD + LOR)/2).
Weekly pattern of drug use: The pattern of drug use over the sampling week for the sites in 
this report cannot be elucidated from the data included in the current report. We present 
only maximum, minimum and average (for the individual sites) (Figure 3) and only average 
(or population weighted average, see above) values for all other graphs. Consistent patterns 
of drug use in Australia from previous wastewater-based epidemiology studies indicate that 
some illicit drugs such as cocaine, MDMA, mephedrone and methylone have high variation 
in weekly consumption rates, with higher consumption on weekends. Other drugs such 
as methylamphetamine, oxycodone and fentanyl appear to have lower daily variation, 
suggesting that their consumption is consistent throughout the week (Lai et al., 2015, 
Tscharke et al., 2016). 
23
Australian Criminal Intelligence Commission 
National Wastewater Drug Monitoring Program—Report 2, July 2017
4: RESULTS
Estimated drug consumption data are presented in several different ways in the following 
sections to allow comparisons of drug use at the individual site level (Section 4.1), between 
states and territories (Section 4.2) and within each state and territory (Section 4.3). We 
recommend exercising caution when comparing results between sites. Although every 
effort has been made to ensure accuracy, population size and estimated consumption 
may be affected by inaccuracies in population figures provided by plants or managing 
agencies. Following release of the 2016 Census data, updated catchment populations 
will be determined and included in the third and subsequent reports. The uncertainties 
in individual population estimates have less impact when data are averaged, for example 
when broader comparisons at the state/territory or international level are undertaken.
4.1: INDIVIDUAL SITE COMPARISON OF DRUG USE IN DECEMBER 2016
4.1.1: TOBACCO AND ALCOHOL
Tobacco consumption was estimated by measuring two nicotine metabolites. The method 
does not distinguish between nicotine intake from tobacco or electronic cigarettes and 
nicotine replacement therapies such as patches and gums. Estimated tobacco consumption 
varied significantly between sites and regions (Figure 4). Regional Queensland and some 
sites in New South Wales and Western Australia had the highest per capita consumption in 
Australia. In general, regional sites had higher average consumption levels (red horizontal 
line, Figure 4) than capital city precincts (dotted blue line, Figure 4). The Northern Territory 
and Tasmania declined to participate in this collection period. Therefore, data for these 
regions are unavailable.
Figure 4: Estimated tobacco consumption in mass of nicotine consumed per day (left 
axis) and number of cigarettes per day (right axis) per thousand people. The number of 
collection days varied from 4–7. 
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Alcohol was measured using a specific metabolite of ethanol. The difference between the 
average capital city and regional centre alcohol consumption was not as pronounced as for 
tobacco (Figure 5). Some regional sites in Western Australia showed a wide range over the 
collection week. Alcohol consumption in regional South Australia and parts of Queensland 
was well below the national average. 
Figure 5: Estimated alcohol consumption in volume consumed per day (left axis) and 
standard drinks per day (right axis) per thousand people. The number of collection days 
varied from 4–7. 
4.1.2: STIMULANTS
The relative estimated consumption levels across the participating sites for three stimulants, 
methylamphetamine, cocaine and MDMA, are described in more detail below.
4.1.2.1: METHYLAMPHETAMINE
Except for tobacco and alcohol, estimated mass loads of methylamphetamine were high 
compared to other substances of abuse. The normalised mass loads in South Australia and 
Western Australia were the highest (Figure 6). A high variability in consumption across the 
nation was evident. One site (120) in regional Western Australia had the highest level on 
a single day, although the average weekly total for the site (black horizontal bar) was not 
substantially different from consumption levels elsewhere in the state (e.g. 102). In contrast, 
another regional site in Western Australia (Site 118) had very low consumption compared 
to the national average. Regional and capital city averages were marginally different, with 
regional consumption being slightly lower for the sites assessed this period. 
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Figure 6: Estimated methylamphetamine consumption in mass consumed per day  
(left axis) and doses per day (right axis) per thousand people. The number of collection 
days varied from 4–7. 
4.1.2.2: AMPHETAMINE
The concentration of amphetamine observed in the August 2016 samples strongly 
correlated with the methylamphetamine concentrations, with approximately seven times 
higher methylamphetamine measured than amphetamine (R2 = 0.77) (see Appendix 4 of 
Report 1) which is consistent with the reported amphetamine excretion range following 
methylamphetamine consumption (Gracia-Lor et al., 2016). Therefore, we assumed 
that the levels of amphetamine we measured were predominantly metabolites of 
methylamphetamine. It is probable that some of the amphetamine measured could be 
a result of amphetamine ingestion. But, due to the much higher methylamphetamine 
consumption and excretion profile, this cannot be confirmed by our present data.
4.1.2.3: COCAINE
Cocaine was measured using its specific metabolite, benzoylecgonine. On a national 
level, capital city areas on average had higher cocaine use than regional centres (Figure 
7). However, some regional areas such as Site 68 in New South Wales and Site 12 in 
Queensland showed use well above the regional average. Most other sites in regional 
Australia showed very little evidence of cocaine use. Capital city New South Wales 
consumed cocaine well above the national average, with Site 8 particularly prominent. On 
average, cocaine consumption in Australia was noticeably lower than methylamphetamine 
levels. 
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Figure 7: Estimated cocaine consumption in mass consumed per day per thousand people 
(left axis) and doses per day (right axis). The number of collection days varied from 4–7. 
4.1.2.4: MDMA (3,4-METHYLENEDIOXYMETHYLAMPHETAMINE)
In comparison with methylamphetamine, estimated consumption of MDMA was low across 
the country (Figure 8). Some exceptions were capital city Site 8 in New South Wales and 
Site 9 in the Australian Capital Territory with large spikes on specific days, and with weekly 
averages higher than measured for the country overall. A similar observation was made at 
Site 68 in regional New South Wales. Nationally, the regional and capital city average MDMA 
consumption were almost identical.
Figure 8: Estimated MDMA consumption in mass consumed per day (left axis) and doses 
per day (right axis) per thousand people. The number of collection days varied from 4–7. 
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4.1.3: PHARMACEUTICAL OPIOIDS
Oxycodone and fentanyl are pharmaceutical substances with abuse potential. The 
metabolism and excretion of both compounds are well characterised. The major metabolite 
of each compound was measured to estimate drug consumption. The Australian Capital 
Territory and South Australia had the highest capital city level of oxycodone (Figure 9). 
Consumption in regional sites was well above capital city levels, resulting in the average 
regional consumption being almost double the capital city national average. 
Figure 9: Estimated oxycodone consumption in mass consumed per day (left axis) and doses 
per day (right axis) per thousand people. The number of collection days varied from 4–7. 
Similar to oxycodone, fentanyl levels were high in many regional centres, notably parts 
of New South Wales, Queensland and South Australia (Figure 10). On average, regional 
consumption was higher than capital city areas. However, large variations were evident 
when comparing sites across Australia.
Figure 10: Estimated fentanyl consumption in mass consumed per day (left axis) and doses 
per day (right axis) per thousand people. The number of collection days varied from 4–7. 
NSW NT QLD SA TAS VIC WAACT
Regional All Site 
Average
Regional
Average
 Capital 
AverageCapital * No Data
0
2
4
6
8
10
12
0
50
100
150
200
250
00
9
00
3
00
6
00
8
02
1
07
1
01
6
02
5
04
0
05
1
06
8
08
1
11
5
01
0
08
5
07
8
00
2
00
5
01
1
01
2
02
0
02
4
02
8
02
9
03
3
03
9
05
3
07
7
00
7
01
3
02
7
05
9
01
7
02
2
06
3
07
6
11
7
11
9
00
4
01
9
04
1
01
8
03
8
04
8
05
8
00
1
06
7
03
7
04
6
06
1
06
2
06
6
11
4
10
1
10
3
10
4
10
2
11
6
11
8
12
0
Estim
ated Consum
ption
(Doses / 1000 People / Day)E
st
im
at
ed
 C
on
su
m
pt
io
n
(m
g 
/ 
10
00
 P
eo
pl
e 
/ 
Da
y)
Oxycodone
Fentanyl
* * * * * * * * * * * * * * * * * * * * * * *
NSW NT QLD SA TAS VIC WAACT
Regional All Site 
Average
 Regional
Average
 Capital 
AverageCapital
0
5
10
15
20
25
30
0
1
2
3
4
5
6
00
9
00
3
00
6
00
8
02
1
07
1
01
6
02
5
04
0
05
1
06
8
08
1
11
5
01
0
08
5
07
8
00
2
00
5
01
1
01
2
02
0
02
4
02
8
02
9
03
3
03
9
05
3
07
7
00
7
01
3
02
7
05
9
01
7
02
2
06
3
07
6
11
7
11
9
00
4
01
9
04
1
01
8
03
8
04
8
05
8
00
1
06
7
03
7
04
6
06
1
06
2
06
6
11
4
10
1
10
3
10
4
10
2
11
6
11
8
12
0
Estim
ated Consum
ption
(Doses / 1000 People / Day)
Es
tim
at
ed
 C
on
su
m
pt
io
n
(m
g 
/ 
10
00
 P
eo
pl
e 
/ 
Da
y)
Fentanyl
* No Data
* * * * * * * * * * * * * * * * * * * * * * *
28
Australian Criminal Intelligence Commission 
National Wastewater Drug Monitoring Program—Report 2, July 2017
 4.1.4: NEW PSYCHOACTIVE SUBSTANCES 
Methylone, mephedrone and two synthetic cannabinoids, JWH-073 and JWH-018, were 
included in the study. Since limited information is available on the human metabolism 
and excretion of these drugs, the parent compound was measured. It is probable that a 
significant proportion of the ingested drug is converted into different metabolites. In this 
collection, only a few sites showed evidence of methylone and mephedrone use. The 
measured levels were mostly below the limits of reporting. Sites that showed the presence 
of the two compounds are qualitatively listed in Table 2 for the December period. No  
JWH-073 or JWH-018 were detected in any samples.
Table 2. The number and code of sites per state and territory where mephedrone and 
methylone were detected in December 2016. The total number of daily samples that were 
assessed in December was 236.
Number of detections Dec 2016 Sites detected Dec 2016
State/territory Mephedrone Methylone Mephedrone Methylone
NT 0 0
ACT 0 7 009
NSW 5 16 068 003, 006, 008, 
016, 068, 115
Qld 1 21 012 002, 011, 
012, 024, 039
SA 4 4 007, 063 059
Tas 0 0
Vic 1 7 067 067
WA 0 14 101, 103, 
104, 102 
Total 11 69   
 
Detection methods for measuring the synthetic cannabinoids were also included in this 
study, but neither compound was detected in any of the samples. MDA had overall low 
detection frequency using direct injection methods. Being a metabolite of MDMA, it was 
assumed that most low levels detected originated from MDMA consumption. This will be 
addressed further in subsequent reports by concentrating the sample using solid phase 
extraction prior to analysis to improve the sensitivity of the method.
4.2: STATE AND TERRITORY COMPARISON OF DRUG USE 
The total level of each drug reported in the preceding August report per state or territory was 
compared with subsequent collection periods. Capital city sites were monitored over weeks 
in October, December 2016 and February 2017. Samples from regional sites were collected 
for up to a week during October and December 2016 and February 2017 in South Australia 
and Western Australia, and December 2016 in other participating states and territories.  
Every effort was made to assess the same sites for each period. However, as the individual 
sites and the number of sites used to generate the population-weighted averages may have 
changed between periods, comparing between time points should be done with caution. This 
would be most evident for the regional averages, which had more variation in participation 
between each period (see Appendix 1 for a comprehensive list of participating sites). 
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4.2.1: TOBACCO AND ALCOHOL
Average tobacco consumption in samples collected from regional sites were generally 
higher when compared to the capital cities (Figure 11 (top)). In the Australian Capital 
Territory and most states, tobacco consumption showed a small increase over the four 
collection periods. For alcohol, the difference between overall capital city and regional 
centre consumption within each state or territory was less pronounced (Figure 11 
(bottom)). No apparent trend was obvious in terms of changes in consumption over time 
within each region.
Figure 11: Estimated average consumption of tobacco (top) and alcohol (bottom) for 
capital city sites and regional sites by state/territory. A standard drink is 10.0 g or 12.5 mL 
and 1 cigarette contains 1.25 mg of nicotine.
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4.2.2: ILLICIT DRUGS
Regional Western Australia had the highest levels of methylamphetamine consumption, 
while Western Australia and South Australia had the highest levels in capital cities (Figure 
12). In both of these states, consumption appeared to peak in October 2016 and has 
declined since. Queensland shows a similar pattern, albeit less pronounced. Additional data 
points will be needed to confirm the decline.
Figure 12: Estimated average consumption of methylamphetamine for capital city sites 
and regional sites by state/territory.
When plotted against historical levels recorded in the three regions, the decline or levelling 
off in use is a reversal in the long term trend (Figure 13). However, whether the downward 
change in consumption is temporary or not, remains to be seen. 
Figure 13: Change in methylamphetamine consumption for sites with historical data. 
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Cocaine consumption in capital city sites in New South Wales continued to dominate the 
national landscape, though the Australian Capital Territory and Victoria showed increases 
from August 2016 to February 2017 (Figure 14). Regional consumption was noticeably lower 
than in capital cities in every state and territory, except Queensland. Cocaine consumption 
in Western Australia remained well below the national average. 
Figure 14: Estimated average consumption of cocaine for capital city sites and regional 
sites by state/territory.
In regions with representative sampling data, no consistent trends in MDMA use were 
evident. MDMA use in the Australian Capital Territory increased dramatically in December 
2016, almost reaching the high levels recorded in the Northern Territory in August 2016 
(Figure 15). In contrast, MDMA use in regional Western Australia and all sites across South 
Australia was well below the national averages. Moreover, decreasing use over time was 
observed in Queensland, Victoria and Western Australia. No further samples were provided 
from the Northern Territory capital city site to put the high August result into context. 
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Figure 15: Estimated average consumption of MDMA for capital city sites and regional 
sites by state/territory.
4.2.3: OPIOIDS
In terms of pharmaceutical opioids, the average oxycodone and fentanyl use was higher 
in regional areas of a number of states (Figure 16). Levels in regional areas were generally 
lower than in the previous reporting period. However, with only two time points in most 
instances, this decline should not be considered significant as population movements or 
short term behavioural changes will dramatically affect the results in small catchments. In 
addition, the variation in participating rural sites (and hence the sampled populations) may 
also have an effect on the observed trend of the population-weighted averages.
Figure 16: Estimated average consumption of oxycodone and fentanyl for capital city sites 
and regional sites by state/territory. 
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Figure 16 (continued): Estimated average consumption of oxycodone and fentanyl for 
capital city sites and regional sites by state/territory. 
The August 2016 fentanyl result for the regional Western Australian site (102) was affected 
by a processing error. This has been corrected in the current report, showing that fentanyl 
use in the region has remained largely steady since that time. 
For the NPS, some drugs such as the cannabinoids were not detected at all. Excretion rates 
for methylone and mephedrone are not yet fully understood and therefore conversion 
factors for the purposes of the set of figures above could not be applied. Nevertheless, 
when these compounds were detected, they were at very low levels compared to 
substances included in Figure 16 (December mephedrone and methylone results are shown 
in Table 2).
4.2.4: CAPITAL CITY AVERAGES
In order to determine representative population trends for the collective catchments 
included in the report over the four time periods, the averaged capital city site populations 
were expressed as the total capital average consumption of illicit stimulants (Figure 17). One 
complication with this type of analysis is that fewer sites were sampled after August 2016, 
so the contributing population was smaller after this date and some approximations had to 
be made to account for the absence of some densely populated regions (e.g. October 2016 
for capital city New South Wales, and Queensland). For the total population included in the 
report, methylamphetamine appeared to peak in October 2016, showing a steady decline in 
the next two collection periods. However, further results are necessary before significance can 
be attributed to the change. MDMA showed very little change, while cocaine levels rose from 
a very low base. 
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Figure 17: The population-weighted average of all capital city sites for methylamphetamine, 
MDMA and cocaine. As Queensland and New South Wales capital city sites were not 
sampled in October 2016, their average consumption in August and December 2016 was 
used to provide the October estimate. 
In terms of legal substances with abuse potential, tobacco consumption as measured by 
two nicotine metabolites showed a small increase over the reporting periods (Figure 18). In 
contrast, the two pharmaceutical opioids included in the study showed an overall decline 
since August 2016. In the case of alcohol, marginal changes were evident.
Figure 18: The population-weighted average of all capital city sites for tobacco, alcohol, 
oxycodone and fentanyl. As Queensland and New South Wales capital city sites were not 
sampled in October 2016, their average consumption in August and December 2016 was 
used to provide the October estimate.
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4.3: DRUG PROFILE FOR EACH STATE AND TERRITORY
To compare usage of drugs of different types within the same region (for example, within 
a state or territory), drug consumption was reported as the number of doses consumed. 
When the amount of drug measured in wastewater was normalised for population size and 
average dose consumed (conversion factors are listed in the first NWDMP report), alcohol 
and tobacco remained consistently the highest consumed drugs in all states and territories. 
For example, the national average consumption of alcohol and tobacco per 1,000 people 
per day were 1,300 cigarettes per 1,000 people (Figure 4) or 1,200 standard drinks per day 
(Figure 5), whereas for methylamphetamine, the national average consumption was closer 
to 35 doses per 1,000 people per day (Figure 6). 
Amongst the illicit drugs and opioids, methylamphetamine consumption was the highest 
across all regions of Australia (Figure 19). This trend was consistent for both capital cities 
and regional sites. Based on the consumption profiles of the other drugs detected in this 
study (cocaine, MDMA, oxycodone and fentanyl), no other consistent patterns of usage 
within the different states and territories were observed; for example, in capital city New 
South Wales, regional South Australia and regional Western Australia, the second highest 
drug consumed was fentanyl, but oxycodone in regional Queensland and Victoria.
Figure 19: Profile of average drug consumption by state or territory. Consumption is 
shown as the number of doses per 1,000 people per day to allow comparison of drugs of 
different types within the same region (state or territory).
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Figure 20: Profile of average drug consumption by state or territory. Consumption is 
shown as the number of doses per 1,000 people per day to allow comparison of drugs of 
different types within the same region (state or territory). 
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7: APPENDICES
APPENDIX 1: FURTHER INFORMATION ON WWTPS
Table A1: Sampling details of each wastewater treatment plant. 
 Capital/Regional
Samples 
Aug 16
Samples 
Oct 16
Samples 
Dec 16
Samples 
Feb 17
Population  
Category
ACT: 009 Capital 7 - 7 7 >150,000
NSW: 003 Capital 7 - 7 4 >150,000
NSW: 006 Capital 7 - 7 7 >150,000
NSW: 008 Capital 6 - 7 7 >150,000
NSW: 021 Capital 7 - - - 30,000 to 150,000
NSW: 071 Capital 7 - - - >150,000
NSW: 016 Regional 5 - 7 - 30,000 to 150,000
NSW: 025 Regional 7 - - - >150,000
NSW: 040 Regional 7 - - - <30,000
NSW: 051 Regional 7 - - - <30,000
NSW: 068 Regional 1 - 4 - >150,000
NSW: 115 Regional - - 7 - 30,000 to 150,000
NT: 010 Capital 7
Declined to participate 
30,000 to 150,000
NT: 078 Regional 7 <30,000
QLD: 002 Capital 7 - 6 6 >150,000
QLD: 005 Capital 7 - - 7 >150,000
QLD: 011 Capital 7 - 7 6 >150,000
QLD: 012 Regional 5 - 7 - >150,000
QLD: 020 Regional 7 - - - <30,000
QLD: 024 Regional 7 - 7 - 30,000 to 150,000
QLD: 028 Regional 7 - 7 - 30,000 to 150,000
QLD: 029 Regional 7 - 7 - 30,000 to 150,000
QLD: 033 Regional 7 - 7 7 30,000 to 150,000
QLD: 039 Regional 7 - 7 - <30,000
QLD: 053 Regional 7 - 3 - <30,000
QLD: 077 Regional 7 7 7 - <30,000
SA: 007 Capital 5 7 7 7 >150,000
SA: 013 Capital 5 7 7 7 >150,000
SA: 027 Capital 5 7 7 7 30,000 to 150,000
SA: 059 Capital 5 7 7 7 30,000 to 150,000
SA: 017 Regional 5 - 4 - <30,000
SA: 022 Regional 5 - 4 - <30,000
SA: 063 Regional 5 - 4 - <30,000
SA: 076 Regional 5 - 4 - <30,000
SA: 119 Regional - - 4 - <30,000
40
Australian Criminal Intelligence Commission 
National Wastewater Drug Monitoring Program—Report 2, July 2017
TAS: 004 Capital 7
Declined to participate
30,000 to 150,000
TAS: 019 Capital 7 30,000 to 150,000
TAS: 041 Capital 7 30,000 to 150,000
TAS: 018 Regional 7 30,000 to 150,000
TAS: 038 Regional 7 <30,000
TAS: 048 Regional 7 <30,000
TAS: 058 Regional 7 <30,000
VIC: 001 Capital 7 7 7 7 >150,000
VIC: 067 Capital 7 7 7 7 >150,000
VIC: 037 Regional 7 - 7 - >150,000
VIC: 046 Regional 7 - - - 30,000 to 150,000
VIC: 061 Regional 7 - 7 - 30,000 to 150,000
VIC: 062 Regional 7 - - - 30,000 to 150,000
VIC: 066 Regional 6 - 7 - 30,000 to 150,000
WA: 101 Capital 7 7 7 7 >150,000
WA: 103 Capital 7 7 7 7 >150,000
WA: 104 Capital 7 7 7 7 >150,000
WA: 102 Regional 7 7 7 7 30,000 to 150,000
WA: 118 Regional - - 7 7 30,000 to 150,000
WA: 120 Regional - - 7 7 <30,000
Total number of samples 329 77 236 135
Table A1 (continued): Sampling details of each wastewater treatment plant. 
 Capital/Regional
Samples 
Aug 16
Samples 
Oct 16
Samples 
Dec 16
Samples 
Feb 17
Population  
Category
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CONCLUSIONS
For the second report of the National Wastewater Drug Monitoring Program, wastewater 
analysis was conducted between October 2016 and February 2017. Findings show that 
alcohol and tobacco consumption remained the highest of the substances tested in all states 
and territories. Methylamphetamine consumption was the next highest of the substances 
tested, indicating that demand for the drug remains strong. However, there was a small 
decrease in methylamphetamine use nationally, although results differed across jurisdictions. 
Use of the pharmaceutical opioids oxycodone and fentanyl remained significant, particularly 
in regional areas. However, on a national level, the overall use declined this reporting period. 
Results for the four new psychoactive substances again supported the assessment that this 
is a niche market which remains small in comparison with traditional illicit drug markets. 
METHYLAMPHETAMINE
In all jurisdictions, methylamphetamine consumption far exceeded the consumption of 
other illicit stimulants and both licit and illicit consumption of oxycodone and fentanyl.4 
Methylamphetamine consumption in capital city locations marginally exceeded 
consumption in regional locations, with consumption highest in South Australia and 
Western Australia, although consumption in both states fell after October 2016. 
The long-term trend identified in wastewater analysis in Queensland and South Australia 
since 2009–10 has shown a consistent pattern of methylamphetamine consumption 
exceeding the consumption of other illicit stimulants. Data from 2010 is available in two 
regional Queensland sites. This data shows that in those locations methylamphetamine 
consumption increased every year until October 2016, after which the level of consumption 
decreased at one site. Similar data is also available for four capital city sites in South 
Australia, and results from these sites show a continuous increase in methylamphetamine 
consumption until August 2016, after which the level of consumption decreased. 
Available data from capital city sites in Perth shows that since 2013 methylamphetamine 
consumption has been relatively constant in the respective catchment areas but 
has decreased since October 2016. Average national capital city consumption of 
methylamphetamine showed little change between August 2016 and February 2017.
The above results are consistent with other publicly available data reported by the Australian 
Criminal Intelligence Commission. For example, during 2015–16 both the number of seizures 
and weight of amphetamine-type stimulants (ATS) (excluding MDMA) detected at the 
Australian border were the second highest on record. The number of ATS (excluding MDMA) 
detections decreased 13.3 per cent from 2014–15 to 2015–16, with the weight detected 
decreasing by 23.4 per cent. It is worth noting that 64.2 per cent of ATS (excluding MDMA) 
detections during 2015–16 were of crystalline methylamphetamine, commonly referred 
to as ice or crystal meth, confirming that this remains the dominant form of the drug in 
Australia. In 2015–16, the number of national ATS seizures increased by 19.1 per cent to a 
record 39,014 seizures, although the weight seized nationally decreased 27.0 per cent—the 
second highest weight on record. National ATS arrests increased 34.3 per cent in 2015–16, to 
a record 47,625. 
4 Throughout this report, all comparisons of the consumption of different drugs are based on doses rather than the weight 
of the respective substances.
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Results from the Drug Use Monitoring in Australia program5 indicate that in 2015–16 the 
self-reported use of methylamphetamine by police detainees overtook that of cannabis. 
For the first time, methylamphetamine became the most commonly reported illicit 
drug used by detainees in the 12 months preceding interview. The self-reported use of 
methylamphetamine by detainees increased from 50.4 per cent in 2014–15 to 59.7 per cent 
in 2015–16. The proportion of detainees testing positive for methylamphetamine increased 
from 38.7 per cent in 2014–15 to 49.0 per cent in 2015–16, and continues to be higher than 
the proportion testing positive for MDMA, heroin, cocaine, benzodiazepines and opiates 
(excluding heroin). In 2015–16, the proportion testing positive for methylamphetamine was 
also higher than the proportion testing positive for cannabis.
The overall picture for methylamphetamine is one of ongoing and strong demand. While 
the National Wastewater Drug Monitoring Program has shown signs that consumption may 
have peaked in late 2016, it is too early to say with any certainty if this recent reduction in 
consumption is the start of a longer term trend. 
AMPHETAMINE
Amphetamine is a metabolite of methylamphetamine consumption. Although it is 
recognised that some forms of amphetamine (such as amphetamine and dexamphetamine) 
are used for both licit and illicit purposes, amphetamine results have not been reported 
separately in this report, as the major source of amphetamine detected in the wastewater 
was methylamphetamine consumption.
COCAINE
Nationally, cocaine consumption in capital city locations was on average almost double 
the level of cocaine consumption in regional locations. Cocaine use remained highest in 
New South Wales, mainly in the capital city locations. However, there was also tangible 
consumption in the Australian Capital Territory, in a regional location in Queensland and 
in Victoria this reporting period. Average national capital city consumption of cocaine 
increased between August 2016 and February 2017, albeit from a low base.
Other publicly available data reported by the Australian Criminal Intelligence Commission 
indicates that both the number and weight of cocaine detections at the Australian border 
increased, with a record 2,777 border detections in 2015–16. National seizures also 
increased, with a record 3,951 cocaine seizures during that period.
Results from the Drug Use Monitoring in Australia (DUMA) program indicate that cocaine 
continues to be one of the least commonly detected drugs among detainees. However,  
the proportion of detainees testing positive for cocaine via urinalysis6 increased from  
0.8 per cent in 2014–15 to 0.9 per cent in 2015–16. Self-reported recent use7 of cocaine  
also increased from 14.2 per cent in 2014–15 to 16.0 per cent in 2015–16.
5 The DUMA program examines drug use and offending patterns among police detainees and comprises an interviewer-
assisted self-report survey and the voluntary provision of a urine sample which is subjected to analysis to detect licit and 
illicit drug use. Detainees can participate in the survey without providing a urine sample. Cases with missing data are 
excluded from the relevant analysis.
6 Cocaine and its metabolite can be detected in urine for 24 to 36 hours after administration.
7 Recent use in the DUMA program refers to self-reported use in the 12 months prior to arrest.
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3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA)
Average national MDMA consumption was almost identical across capital city and regional 
locations. MDMA consumption in the Australian Capital Territory increased significantly in 
December 2016, before reducing to a relatively low level in February 2017. Consumption of 
MDMA across the rest of the country was unremarkable, with the average national capital 
city consumption of MDMA almost halving between August 2016 and February 2017.
The subdued picture of the domestic MDMA market that emerges from these results is 
consistent with other publicly available data reported by the Australian Criminal Intelligence 
Commission. For example, the number and weight of MDMA detections at the Australian border 
decreased in 2015–16. The number of national MDMA seizures increased by 10.1 per cent in 
2015–16 to 5,967, while the weight of MDMA seized decreased by 28.7 per cent. The number of 
national MDMA arrests increased by 24.1 per cent to 6,272.
Additionally, results from the DUMA program indicate that the proportion of detainees testing 
positive to MDMA via urinalysis increased from 1.3 per cent in 2014–15 to 1.9 per cent in 
2015–16. Over the last decade the proportion of detainees testing positive to MDMA has 
remained low (under 2.9 per cent). Self-reported recent use of MDMA8 increased from  
14.7 per cent in 2014–15 to 16.2 per cent in 2015–16.
3,4-METHYLENEDIOXYAMPHETAMINE (MDA)
MDA is a metabolite of MDMA. Although it is recognised that there is an illicit market for 
MDA in Australia, MDA results have not been reported separately in this report, as the major 
source of MDA detected in the wastewater was MDMA consumption and there is no data on 
the size of the illicit MDA market.
JWH-018 AND JWH-073
Methods for measuring the synthetic cannabinoids JWH-018 and JWH-073 were also 
included but failed to detect the compounds in sites across Australia.
MEPHEDRONE
Mephedrone was detected 11 times at a total of five sites across New South Wales, 
Queensland, South Australia and Victoria, but the quantity of the substance was mostly 
below the level at which it could reliably be quantified. 
METHYLONE
Methylone was detected 69 times at a total of 18 sites in all states and territories except 
South Australia and Victoria, but the quantity of the substance was mostly below the level at 
which it could reliably be quantified. 
8 The self-report question includes use of ecstasy/MDMA in the 12 months prior to arrest.
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OXYCODONE
Oxycodone was detected in all jurisdictions, with the consumption of oxycodone, 
which may be licit or illicit, exceeding the use of cocaine and MDMA in all jurisdictions. 
Nationally, consumption in regional locations was on average almost double the capital 
city consumption. South Australia and the Australian Capital Territory had the highest 
oxycodone consumption in capital city locations, while regional consumption in parts 
of New South Wales, Queensland and Victoria was above the national average. Average 
national capital city consumption of oxycodone reduced significantly between August 2016 
and February 2017.
FENTANYL
The consumption of fentanyl, which may be licit or illicit, exceeded the use of cocaine 
and MDMA in all jurisdictions this reporting period. Fentanyl consumption in regional 
locations exceeded consumption in capital city locations in all jurisdictions except Western 
Australia. Consumption was high in many regional centres, particularly in New South Wales, 
Queensland and South Australia. Consumption of fentanyl reduced generally during the 
period covered by this report, with average national capital city consumption also reducing 
significantly between August 2016 and February 2017.
TOBACCO
In most jurisdictions and in capital city locations, tobacco consumption increased slightly 
from August 2016 to February 2017. Average national tobacco consumption in regional 
locations exceeded consumption in capital city locations—a trend which also extended to 
most jurisdictions. 
ALCOHOL
There was no significant trend in alcohol consumption nationally this reporting period. 
Average national alcohol consumption was slightly higher in capital city locations than 
regional locations, though alcohol consumption in regional South Australia and parts of 
Queensland was well below the national average. 
NEXT REPORT
The third report of the National Wastewater Drug Monitoring Program will be publicly 
released in November 2017.
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